Technologies

The technology, developed by CNR-ICB, is based on an innovative bioprocess called "Caphnophilic (CO2-requiring) Lactic Fermentation (CLF)”, developed in the hyperthermophilic bacterium Thermotoga neapolitana (EP patent: EP2948556B1), which allows the production of "green" hydrogen and capture and valorization of CO2 in L -lactic acid (98% e.e.).

It enables a systemic and evolutionary development of people, organisations and territories by overcoming the criticality of traditional approaches, which get stuck because of rationalistic reductions in complexity, as well as lack of motivation. This responds to the social sustainability needs highlighted by the UN 2030 agenda. The methodology is based on 3 pillars:

Celiac disease and non-celiac gluten sensitivity affect a large portion of the world population. Furthermore, the percentage of people who adopt the gluten free diet is constantly increasing because it is perceived to be healthier. We have previously developed a food grade enzymatic procedure (transamidation) for wheat flour capable of making gluten unable to induce the inflammatory response in the intestine of celiac disease patients.

Geopolymers belong to the class of chemically bonded ceramics: they are synthesized at low temperatures and are eco-friendly, as besides the low consolidation temperature required by the process they can be produced from secondary raw materials and industrial waste of various kinds, thus reducing the energy demand and the environmental impact of the entire production cycle. Materials such as fly ash, steel mill slag, biomass ash, sludge and silt, extractive residues, mineral and ceramic powders, organic or inorganic waste fibers, plastics, etc.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.